Clinical trials show that discontinuing GLP-1 therapy leads to weight regain in approximately 70% of patients within one year, underscoring why these medications function best as long-term treatment rather than temporary interventions
This makes Mounjaro Weight Loss Injection in Malaysia different from GLP-1-only treatments, such as Ozempic and Wegovy
Fernandes-Santos C, Zhang Z, Morgan DA, Guo D-F, Russo AF, Rahmouni K
According to researchers from the University of Pennsylvania and Cedars-Sinai Medical Center, the number of non-diabetic patients starting these medications jumped from 21,000 in 2019 to over 174,000 in 2023
Sibutramine (marketed as Meridia) was withdrawn after heart attacks spiked